Off-Label Use of Septal Occluder Devices for Recurrent Tricuspid Regurgitation Following TEER

Read full text Summarise with VIRAT
Authors: Firas Jaly, Holger Priebe‐Brämer, Boris Dickmann, Jadwiga Klajn, Hans-Jörg Hippe
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Recurrent severe tricuspid regurgitation (TR) after transcatheter edge-to-edge repair (TEER) remains a therapeutic dilemma when redo clipping, surgery, or heterotopic caval valve implantation are not feasible. CASE SUMMARY: We report 4 high-risk patients with massive to torrential TR due to interclip coaptation defects who were treated with off-label percutaneous closure using septal occluder devices. Procedural strategy evolved from transfemoral to right internal jugular access to improve coaxial alignment and deployment control. Early atrial septal occluders embolized, whereas muscular ventricular septal defect occluders, with a broader waist, provided stable anchoring and durable TR reduction. Balloon test occlusion and meticulous intraprocedural imaging were essential to avoid iatrogenic tricuspid stenosis. Clinical outcomes ranged from sustained symptomatic improvement to persistent right heart failure in advanced disease. Together, these cases suggest that in anatomically selected patients, occluder implantation may represent a feasible salvage strategy for recurrent TR after TEER when established therapies are not possible.

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Cardiac Structural Anomalies and Repair Cardiac Arrhythmias and Treatments

Publication details

Journal / source
JACC Case Reports
Volume
31
Issue
18
Pages
107719–107719
Publication date
28 March 2026
Language
EN